The following DAIDS-sponsored contract resources are available to assist investigators in the evaluation of novel anti-TB therapies.
Compound Acquisition
Novel synthetic and pure natural product compounds (~6000 per year) are actively solicited as potential anti-tubercular therapies. Compounds are inventoried and then shipped to DAIDS-sponsored TB testing facilities.
In Vitro Efficacy Evaluations
- Potential therapeutic agents can be evaluated for cytotoxicity and for efficacy against both wild type and drug-resistant strains of Mycobacterium tuberculosis
- Therapeutic agents can be evaluated either alone or in combination with other agents
In Vivo Efficacy Evaluations
- A model utilizing M. tuberculosis infection of mice is available. Microbiologic and histologic parameters can be evaluated.
- Compounds are evaluated for in vitro efficacy against the microbial strains used in the model prior to initiating in vivo studies
- Therapeutic agents can be evaluated either alone or in combination with other agents
- Both anti-tubercular and immune-based therapies can be evaluated.
Accessing These Resources
For further information please contact Dr. Barbara Laughon (phone: 301-402-2304; e-mail: bl17u@nih.gov)